Global Gemcitabine HCL Market Size, Share, Growth, Trends, and Forecast 2019-2026

The global gemcitabine HCl market size is projected to reach over US$ 900 Mn by 2027, expanding at a CAGR of nearly 7% from 2020 to 2027.

Initiatives by key players, and the growing number of patient support organizations and governmental & healthcare agencies to spread awareness regarding cancer is projected to drive the global gemcitabine HCl market. Technical advancements in the manufacturing of generic drugs have also led to an increase in the demand for gemcitabine HCl, which is expected to propel the global gemcitabine HCl market in the near future.

Overview

• The gemcitabine HCl market report offers exhaustive segmentation of the global market based on type, application, and end user. In terms of type, the gemcitabine HCl market has been segmented into branded and generic. The generic segment held a major share in the gemcitabine HCl market in 2018. Low cost, similar efficacy, and increase in the demand for generic drugs are the factors driving this segment in the global gemcitabine HCl market. 

• Based on application, the global gemcitabine HCl market has been classified into pancreatic cancer, breast cancer, ovarian cancer, non-small-cell lung carcinoma (NSCLC), and others. The pancreatic cancer segment held a leading market share in 2018, owing to increased incidences of this disease. Pancreatic cancer usually affects the geriatric population. Increase in the geriatric population is one of the factors fueling the growth of this segment in the global gemcitabine HCl market. 

• In terms of end user, the global gemcitabine HCl market has been divided into hospitals, cancer centers, and others. The hospitals segment is anticipated to grow at a rapid pace in the next few years. The adoption of healthcare information systems in hospitals is rising in Asia Pacific due to an increase in the number of private sector hospitals in the region. This, in turn, is likely propel the gemcitabine HCl market in the next few years. 

• Geographically, the global gemcitabine HCl market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, North America and Asia Pacific gemcitabine HCl markets are anticipated to drive global demand. The gemcitabine HCl market in North America is expected to expand at a high CAGR from 2019 to 2027. This is attributed to the adoption of cost-effective genetic drugs, expiry of patented products, proper guidelines for the manufactures of biosimilars, and the presence of a large number of players in the generics market in the region.
• The demand for cost-effective generic cancer drugs is rising, especially in emerging countries such as China, India, and Brazil. This is due to the increase in the incidences of cancer and a surge in the acceptance of generic drugs in the global gemcitabine HCl market. 

Generic Segment Expected to Grow at a Rapid Pace in the Gemcitabine HCl Market

• The report offers exhaustive segmentation of the global gemcitabine HCl market based on type, application, and end user. In terms of type, the gemcitabine HCl market has been segmented into generic and branded.
• The generic segment held a major share in the gemcitabine HCl market in 2018. This segment is likely to grow at a rapid pace in the next few years, attributed to the strong pipeline of generic gemcitabine HCl drugs. In order to market a generic drug, a company needs to file an Abbreviated New Drug Application (ANDA). An ANDA approval implies that the generic drug is comparable to the original drug in terms of strength, dosage form and quality, route of administration, performance, characteristics, and intended use.
• However, companies cannot manufacture a generic unless the patent of a drug expires. After the patent loss of Gemzar in 2010, several generics have entered the gemcitabine HCl market. The demand for low-cost substitutes of gemcitabine HCl is high in low- and middle-income countries in the Asia Pacific, Africa, and Latin America gemcitabine HCl markets.
• This has increased the number of gemcitabine API manufacturers, since pharmaceutical drug manufacturers do not have enough in-house capacity to meet the demand. 

Pancreatic Cancer & Hospitals Segments to Capture Prominent Market Shares

• The pancreatic cancer segment held a major market share in 2018, owing to the rise in incidences of pancreatic cancer. According to WHO, there will be nearly 638,647 new cases of pancreatic cancer in 2030, as against 458,918 in 2018.
• This increase in the number of cases is primarily due to the increasing geriatric population, and the associated risk factors becoming increasingly common among the population. This is expected to drive the global gemcitabine HCl market in the new few years.
• The hospitals segment is expected to grow at a rapid pace in the next few years. Hospitals provide low-cost treatment to all citizens across the globe.
• Strategic collaborations with hospitals for cancer research studies on several hundred patients with a variety of cancer types have helped companies come up with novel drugs and therapeutic treatments.
• The hospital infrastructure in emerging countries is developing at a significant pace, as various regional and national governments (for example Saudi Arabia) are encouraging private players to enter the healthcare services sector.

Asia Pacific Gemcitabine HCl Market Expected to Expand at a High CAGR

• North America is likely to be a prominent region in the global gemcitabine HCl market during the forecast period. Easy adoption of new products, presence of key players, and favorable reimbursement policies are attributed to the region’s dominance in the global gemcitabine HCl market. The gemcitabine HCl markets in Europe and Asia Pacific are also projected to grow at a rapid pace from 2019 to 2027.
• The gemcitabine HCl market in these regions are anticipated to be driven by the rise in the demand for cost-effective generic cancer drugs, especially in emerging countries such as China, India, and Brazil, due to an increase in the incidences of cancer and a surge in the acceptance of generic drugs. Additionally, India- and China-based drug manufacturers have a strong presence in the global gemcitabine HCl market. Gemcitabine API manufacturers in India have been investing to comply with U.S. FDA regulations and to win contracts from U.S.-based companies, and have been filing DMF applications. This is expected to boost the global gemcitabine HCl market in the coming years.
• Additionally, initiatives by key players, patient support organizations, and governmental & healthcare agencies to spread awareness about cancer are expected to boost the growth of the gemcitabine HCl market in these regions. Technical advancements in the manufacture of generic drugs have also led to an increase in the demand for gemcitabine HCl, which is expected to propel the global gemcitabine HCl market in the near future. 

The report analyzes and forecasts the gemcitabine HCl market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.

This report first introduces the background of gemcitabine HCl, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major gemcitabine HCl companies.

Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of gemcitabine HCl upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of gemcitabine HCl and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.

The report comprises a detailed value chain analysis, which provides a comprehensive view of the global gemcitabine HCl market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view of the gemcitabine HCl market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report provides size (in terms of volume and value) of gemcitabine HCl market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

Report Segmentation:

By Type
Branded
Generic

By Application
Pancreatic Cancer
Breast Cancer
Ovarian Cancer
Non-small-cell-lung Carcinoma (NSCLC)
Others

By End User
Hospitals
Cancer Centers
Others

By Region
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

The Competitive Landscape

The gemcitabine HCl market shows a high level of consolidation, with Eli Lily and Company, Teva Pharmaceuticals Industries Ltd., and Sun Pharmaceutical Industries Ltd. operating at the top of the market space.

Considering the nature of the product, maximization of drug potential and their commercialization continue to be influencing factors, and to stay competitive, many of these leading players are collaborating with important stakeholders in order to understand the challenges in developing effective gemcitabine HCl with minimum side effects. For instance, in 2018, Eli Liliy and Company collaborated with ARMO Biosciences Inc. to bolster Eli Liliy’s oncology program through the addition of ARMO's lead product candidate, pegilodecakin.

Strategic mergers and acquisitions to strengthen the therapeutic business and licensing agreements also remain a focus area of key manufacturers. In addition, as the importance of new product approval and commercialization intensifies, many players are entering into strategic partnerships and distribution agreements. It is highly likely that, companies such as Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., and Mylan N.V. will continue to emphasize on business partnerships to stay ahead of their competitors.

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.

Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

The study objectives of this report are:

• To analyze and study the global gemcitabine HCl capacity, production, value, consumption, status (2014-2018) and forecast (2019-2026);
• Market value USD Million and volume Units Million data for each segment and sub-segment
• Focuses on the key gemcitabine HCl manufacturers, to study the capacity, production, value, market share and development plans in future.
• Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
• To identify significant trends and factors driving or inhibiting the market growth.
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
• To strategically profile the key players and comprehensively analyze their growth strategies.